. Author manuscript; available in PMC: 2010 Apr 14.

Published in final edited form as: N Engl J Med. 2009 Apr 1;360(18):1815–1826. doi: 10.1056/NEJMoa0807252

Table 3.

Risk of Death Associated with Deferral of Antiretroviral Therapy, According to CD4+ Count at Baseline, with Adjustment for HIV RNA Level, Age, and Sex.^*

Variable	351-to-500 CD4+ Count		More-Than-500 CD4+ Count
	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value
Without inclusion of HIV RNA data
Deferral of antiretroviral therapy	1.69 (1.26–2.26)	<0.001	1.94 (1.37–2.79)	<0.001
Female sex	1.21 (0.89–1.64)	0.24	1.85 (1.33–2.59)	<0.001
Older age (per 10-yr increment)	1.68 (1.48–1.91)	<0.001	1.83 (1.62–2.06)	<0.001
Baseline CD4+ count (per 100 cells/mm³)	1.13 (0.72–1.78)	0.59	0.93 (0.87–0.99)	0.03
With inclusion of HIV RNA data
Deferral of antiretroviral therapy	1.63 (1.21–2.19)	0.002	1.85 (1.20–2.86)	0.006
Female sex	1.47 (1.02–2.12)	0.04	1.35 (0.85–2.15)	0.20
Older age (per 10-year increment)	1.89 (1.69–2.11)	<0.001	1.81 (1.58–2.07)	<0.001
Baseline CD4+ count (per 100 cells/mm³)	0.74 (0.55–1.00)	0.06	0.97 (0.89–1.05)	0.45
Baseline HIV RNA level (per log₁₀ copies/ml)	1.11 (0.96–1.28)	0.15	1.13 (0.96–1.33)	0.14

The CD4+ count was measured in cells per cubic millimeter. Results were calculated with the use of Cox regression analyses with inverse probability-of-censoring weights. HIV denotes human immunodeficiency virus.